Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Germany’s Added Benefit System May Gain Credibility As It Lauds Zytiga And Cans Trajenta

Executive Summary

Decisions by Germany’s drug benefit assessor, IQWiG, to recommend novel prostate cancer treatment Zytiga and reject me-too diabetes treatment Trajenta may allay confusion over just how well the country’s new added value assessment process is working


Related Content

Trajenta’s German Renaissance Nipped In The Bud; Revised Dossier Falls Short
Boehringer Ingelheim Shrugs Off Patent Cliff, Returns To Sales Growth
European Regulatory Round-Up: New Faces; Revised Guidances; More Cost Controls
The Year Ahead In Europe: More Price Cuts, More Austerity
Intermune’s Esbriet Flops In Front Of IQWiG
AZ’s Brilinta Is First Drug To Clear AMNOG Assessment, While Merck’s Victrelis Limps Forward
German Reimbursement Decisions Will Remain Officially Opaque In New Law
J&J’s Zytiga –The Anatomy Of A Cancer Launch
Medivation Aims To Capture Prostate Cancer Market, One Trial At A Time
German Reimbursement Assessment Process Fells Third Rx Victim


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts